Trial Profile
Pilot study of the effects on cardiac diastolic function of GC811007, a fructosamine oxidase inhibitor, in patients with Type 2 diabetes and diabetic cardiomyopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Trientine (Primary)
- Indications Diabetic cardiomyopathy
- Focus Therapeutic Use
- Acronyms INFO-CARDIAC
- 01 Apr 2009 Results publiahed in Diabetologia.
- 27 Jan 2009 New trial record.